US EditionUS health officials advise older travelers not to get a chikungunya vaccine
- The FDA and CDC advised U.S. Travelers age 60 and older to temporarily stop receiving Valneva's Ixchiq chikungunya vaccine on May 9, 2025, amid safety concerns.
- This recommendation comes after reports of severe health complications, such as neurological and cardiac issues, primarily affecting individuals aged 62 and older with preexisting conditions, which have resulted in multiple hospitalizations and two fatalities.
- Ixchiq, approved in November 2023, contains a weakened chikungunya virus and has been distributed worldwide with about 80,000 doses administered, while chikungunya causes fever and joint pain via mosquito bites.
- As of May 7, 2025, 17 serious global adverse event reports, including neurological and cardiac symptoms, have been tracked, leading U.S. Advisors to issue a precaution for older adults and European regulators to review the cases.
- The FDA is currently reevaluating the benefit-risk profile of the Ixchiq vaccine for individuals aged 60 and above, while Bavarian Nordic’s Vimkunya has been suggested as an alternative option for travelers aged 12 and older.
54 Articles
54 Articles
ABC FOX Montana
U.S. Advises Older Travelers to Avoid Chikungunya Vaccine
Key Takeaways
Associated Press News
US health officials advise older travelers not to get a chikungunya vaccine
The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it investigates possible side effects.
FDA/CDC Call Time Out on Ixchiq Vaccine for Older Adults
(MedPage Today) -- Hold off on inoculating people ages 60 and older against chikungunya infection with the Ixchiq vaccine, the FDA and CDC jointly recommended amidst an investigation into adverse events. Two fatalities have been reported among...
After 2 reported deaths, health officials tell Ixchiq users age 60+ to stop vaccine temporarily
The Trump administration's FDA and CDC is advising U.S. patients using the drug Ixchiq to hold off while U.S. health officials seek newer information on vaccine results in the global fight against chikungunya virus.
US Health Agencies Recommend Pausing Valneva's Chikungunya Vaccine For Older Adults After Adverse Events - Valneva (NASDAQ:VALN)
The Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) have advised a temporary halt in administering the chikungunya vaccine Valneva SE’s (NASDAQ:VALN) Ixchiq to adults aged 60 and older as they investigate reports of serious adverse events, including neurological and cardiac complications, following vaccination. As of May 7, 2025, 17 serious adverse events, including two deaths, have been reported globa…
Coverage Details
Bias Distribution
- 69% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
